Expertise in
15
conditions

Dr. Iftekhar Khan

Hematology | Oncology
Bayhealth Medical Center, Inc Oncology
100 Wellness Way, 
Milford, DE 
Offers Telehealth
Expertise in
15
conditions
Bayhealth Medical Center, Inc Oncology
100 Wellness Way, 
Milford, DE 

Overview

Iftekhar Khan is a Hematologist and an Oncologist practicing medicine in Milford, Delaware.

Dr. Khan is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Pulmonary Embolism, Thrombocytopenia, and Polycythemia Vera.

He is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 17 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in DE

Hospital Affiliations

Bayhealth Hospital, Sussex Campus
Bayhealth Medical Center, Kent Campus

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Bayhealth Medical Center, Inc Oncology
100 Wellness Way, Milford, DE 19963
Other Locations
Bayhealth Cancer Center, Kent Campus
640 S State St, Dover, DE 19901

Additional Areas of Focus

Dr. Khan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 2
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Other, Drug
View 9 Less Clinical Trials

8 Total Publications

A retrospective study to assess the accuracy of syphilis rapid test by chemiluminescent microparticle immunoassay (CIA) in volunteer blood donors.
A retrospective study to assess the accuracy of syphilis rapid test by chemiluminescent microparticle immunoassay (CIA) in volunteer blood donors.
Journal: Indian journal of sexually transmitted diseases and AIDS
Published: September 19, 2024
Similar Doctors
Expertise in
48
conditions
Dr. Dhaval R. Shah
Hematology | Oncology
Expertise in
48
conditions
Dr. Dhaval R. Shah
Hematology | Oncology
Referral may be required

Office

4701 Ogletown Stanton Rd Ste 3400, 
Newark, DE 
 (37.9 miles away)
302-366-1200
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Dhaval Shah is a Hematologist and an Oncologist practicing medicine in Newark, Delaware. Dr. Shah is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Urothelial Cancer, Lung Cancer, and Bone Marrow Aspiration. Dr. Shah is currently accepting new patients.

Expertise in
58
conditions
Dr. David Smith
Hematology | Oncology
Expertise in
58
conditions
Dr. David Smith
Hematology | Oncology
Referral may be required

Bay Hematology Oncology P.A.

2977 4H Park Rd Ste 102, 
Centreville, MD 
 (28.8 miles away)
410-758-4030
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Smith is a Hematologist and an Oncologist practicing medicine in Centreville, Maryland. Dr. Smith is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Adult Immune Thrombocytopenia, and Myelodysplastic Syndrome (MDS). Dr. Smith is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required
Before you request

Memorial Sloan Kettering Cancer Center

480 Red Hill Road, 
Middletown, NJ 
 (37.8 miles away)
646-888-4219
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Konner is an Oncologist practicing medicine in Middletown, New Jersey. Dr. Konner is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, and Salpingo-Oophorectomy. Dr. Konner is currently accepting new patients.

Frequently Asked Questions about Dr. Iftekhar Khan

How do I make an appointment with Dr. Iftekhar Khan?

You can book an appointment with Dr. Iftekhar Khan by calling their office at 302-744-7994. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Iftekhar Khan a top-rated expert for Monoclonal Gammopathy of Undetermined Significance (MGUS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Iftekhar Khan is classified as an Distinguished expert for Monoclonal Gammopathy of Undetermined Significance (MGUS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Iftekhar Khan specialize in?

While Dr. Iftekhar Khan is a Hematology, they have specific expertise in Monoclonal Gammopathy of Undetermined Significance (MGUS), Pulmonary Embolism, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Iftekhar Khan participate in research or clinical trials?

Yes. Dr. Iftekhar Khan has published 8 articles and abstracts on conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS). You can view a list of Dr. Iftekhar Khan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Iftekhar Khan accept my insurance?

Dr. Iftekhar Khan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 302-744-7994 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khan's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 63 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile